No profile data available.
Rocket Pharmaceuticals, Inc. (RCKT) is a healthcare company in the blood disorder treatment drugs industry, based in Cranbury, United States, with about 202 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$223.12 million. Its market capitalization was $281.02 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Rocket Pharmaceuticals reported $0 in revenue for fiscal year 2025.
$281.02 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Ultragenyx Pharmaceutical Inc. (RARE), Ardelyx, Inc. (ARDX), Geron Corporation (GERN), Keros Therapeutics, Inc. (KROS).